Splenomegaly News and Research

RSS

Enlargement of the spleen is called splenomegaly and can occur as a result of many infections, tumors, and hereditary or acquired conditions of the blood leading to hemolysis. The enlarged spleen may also become overactive, devouring too many blood cells and producing other symptoms.

Study reveals anti-inflammatory power of Black Soldier Fly Larvae oil in inflammatory-related conditions

New study reveals the anti-inflammatory power of Black Soldier Fly Larvae (BSFL) oil, shedding light on its potential to alleviate inflammation in conditions like ulcerative colitis.

21 Aug 2023

Researchers uncover genetic machinery responsible for EBV-induced B cell growth transformation

B cells or B lymphocytes are an important part of the body's immune system. When healthy B cells are infected with the Epstein-Barr virus (EBV), they undergo growth transformation, a process that immortalizes B cells, leading to their uncontrolled proliferation.

7 Aug 2023

Using AI might afford large-scale evaluation for splenomegaly on CT examinations

According to an accepted manuscript published in ARRS' own American Journal of Roentgenology (AJR), using an automated deep-learning AI tool, as well as weight-based volumetric thresholds, might afford large-scale evaluation for splenomegaly on CT examinations performed for any indication.

3 Jul 2023

Mast cells play a crucial role in the development of chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow.

16 May 2023

Pioneering AI-based approach identifies rare disease patients using electronic health records

Research paper describes the use of Symptoma's AI-based approach to identify patients with Pompe disease from retrospective electronic health records. The study found a prevalence of one in every 18,427 people for Pompe disease in the greater Salzburg region and established phenotypes for patient cohorts with an onset of symptoms above or below 1 year of age.

11 May 2023

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 Jan 2023

Molecular virologist receives nearly $2 million NIH grant renewal to study hepatitis E virus

For decades, University Distinguished Professor of Molecular Virology X.J. Meng and his lab at the Virginia-Maryland College of Veterinary Medicine have studied hepatitis E virus (HEV), the causative agent of hepatitis E in humans.

21 Jun 2019

Study reveals how a regulatory molecule ensures appropriate supply of blood cells

The body needs to create a continuous supply of blood cells to enter circulation. Blood cells have a wide variety of functions ranging from supplying oxygen to tissues, fighting infections, and enabling the blood to clot upon injury.

13 Mar 2019

Hedgehog blockade promising in myeloid malignancies

Phase I trial results published in The Lancet Haematology show that the hedgehog signalling pathway antagonist PF-04449913 is tolerable and has activity in patients with haematological cancers.

5 Aug 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.

30 May 2015

Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Results from a study presented today at The International Liver Congress 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.

25 Apr 2015

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.

16 Mar 2015

AfriCoLeish launches Phase III clinical study to test 2 treatments for HIV-VL co-infected patients

The international research & development (R&D) consortium, AfriCoLeish, formed by six research organizations from East Africa and Europe, has launched a Phase III clinical study to address the extreme difficulty in treating visceral leishmaniasis (VL) in patients who also are HIV-positive.

6 Oct 2014

Researchers review effectiveness of RDTs in diagnosing visceral leishmaniasis

Researchers from the Cochrane Infectious Disease Group, co-ordinated through the editorial base in LSTM, conducted an independent review into the effectiveness of rapid diagnostic tests in diagnosing patients with visceral leishmaniasis (VL), published in The Cochrane Library today.

20 Jun 2014

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV).

4 Jun 2014

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.

7 Mar 2014

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

New method that targets mosquito larvae and pupae may help control malaria

A malaria control method that targets mosquito larvae and pupae as they mature in standing water could be an important supplementary measure in the fight against the disease, according to a new report.

29 Aug 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.

3 Jul 2013

Preclinical study shows PLX cells may help reverse symptoms associated with preeclampsia

Could the answer to repairing the ailing placenta in preeclampsia lie within the stem cells of a healthy placenta? New promising evidence may lead scientists to answer that question.

17 May 2013